MR Imaging Biomarkers to Monitor Early Response to Hypoxia-Activated Prodrug TH-302 in Pancreatic Cancer Xenografts

TH-302 is a hypoxia-activated prodrug known to activate selectively under the hypoxic conditions commonly found in solid tumors. It is currently being evaluated in clinical trials, including two trials in Pancreatic Ductal Adenocarcinomas (PDAC). The current study was undertaken to evaluate imaging...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:PLoS One
Autores principales: Zhang, Xiaomeng, Wojtkowiak, Jonathan W., Martinez, Gary V., Cornnell, Heather H., Hart, Charles P., Baker, Amanda F., Gillies, Robert
Formato: Artigo
Lenguaje:Inglês
Publicado: Public Library of Science 2016
Materias:
Research Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4882075/
https://ncbi.nlm.nih.gov/pubmed/27227903
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0155289
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares